Cargando…
NQO1 is Required for β-Lapachone-Mediated Downregulation of Breast-Cancer Stem-Cell Activity
Cancer stem cells (CSCs) exhibit self-renewal activity and give rise to other cell types in tumors. Due to the infinite proliferative potential of CSCs, drugs targeting these cells are necessary to completely inhibit cancer development. The β-lapachone (bL) compound is widely used to treat cancer de...
Autores principales: | Kim, Dong Wook, Cho, Je-Yoel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6321092/ https://www.ncbi.nlm.nih.gov/pubmed/30513573 http://dx.doi.org/10.3390/ijms19123813 |
Ejemplares similares
-
β-lapachone suppresses tumour progression by inhibiting epithelial-to-mesenchymal transition in NQO1-positive breast cancers
por: Yang, Yang, et al.
Publicado: (2017) -
Phase 1 study of ARQ 761, a β-lapachone analogue that promotes NQO1-mediated programmed cancer cell necrosis
por: Gerber, David E., et al.
Publicado: (2018) -
β-lapachone ameliorates murine cisplatin nephrotoxicty – NAD+, NQO1, and SIRT1 at the crossroads of metabolism, injury, and inflammation
por: Lu, Christopher Y.
Publicado: (2014) -
β-Lapachone Induces Acute Oxidative Stress in Rat Primary Astrocyte Cultures that is Terminated by the NQO1-Inhibitor Dicoumarol
por: Steinmeier, Johann, et al.
Publicado: (2020) -
Tumor-selective use of DNA base excision repair inhibition in pancreatic cancer using the NQO1 bioactivatable drug, β-lapachone
por: Chakrabarti, Gaurab, et al.
Publicado: (2015)